Leukemia is a clonal disease caused due to mutation of human hematopoietic stem cells, can cause symptoms like bleeding, anemia, organ infiltration and intestinal function failure of patients, and is a human disease of great harm. There is also a big leukemia patient group in China, growing by 30-40 thousand patients every year; the leukemia incidence even tops various tumor diseases among children. It is very urgent that leukemia be effectively treated.
|
Drug name |
Target |
Developed by |
|
Imatinib |
KIT/PDGFR/ABL |
Novartis |
|
Nilotinib |
ABL |
Novartis |
|
Dasatinib |
ABL |
BMS |
|
Bosutinib |
ABL |
Wyeth |
|
Ponatinib |
ABL/FGFR1-3/FLT3/VEGFR2 |
Ariad |
|
Ibrutinib |
BTK |
J & J |
|
Obinutuzumab |
CD20 |
Roche |
|
Ofatumumab |
CD20 |
GSK/Novartis |
|
Rituximab |
CD20 |
Roche (Genentech) |
|
Alemtuzumab |
CD52 |
Biogen |
|
Idelalisib |
PI3Kδ |
Gilead |
|
Blinatumomab |
CD19/CD3 |
Amgen |
|
Venetociax |
BCL2 |
AbbVie & Roche |
Table 1 Global leukemia targeting drugs

Novartis started early among the leukemia drug developing companies and has been leading in the field. Both the two small molecule drugs against leukemia under Novartis: Imatinib and Nilotinib have been marketed in China. As an oral leukemia drug, Imatinib can be used to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the blast phase and accelerated phase and treat the chronic-phase patients after failure of the interferon therapy. This drug entered the Chinese market early in 2002 and kept growing within more than 10 years, being the preferred drug of most leukemia patients, however, Imatinib’s share has been on a downward trend for Novartis in recent years due to the patent expiration in each country (including China). China approved the market...










(All Rights Reserved)